1. Does clinically measured walking capacity contribute to real-world walking performance in Parkinson's disease?
- Author
-
Jenna A. Zajac, James T. Cavanaugh, Teresa Baker, Ryan P. Duncan, Daniel Fulford, Jaimie Girnis, Michael LaValley, Timothy Nordahl, Franchino Porciuncula, Kerri S. Rawson, Marie Saint-Hilaire, Cathi A. Thomas, Gammon M. Earhart, and Terry D. Ellis
- Subjects
Cross-Sectional Studies ,Neurology ,Humans ,Parkinson Disease ,Walking ,Fitness Trackers ,Neurology (clinical) ,Geriatrics and Gerontology ,Walking Speed - Abstract
The study examined how clinically measured walking capacity contributes to real-world walking performance in persons with Parkinson's disease (PD).Cross-sectional baseline data (n = 82) from a PD clinical trial were analyzed. The 6-Minute Walk Test (6MWT) and 10-Meter Walk Test (10MWT) were used to generate capacity metrics of walking endurance and fast gait speed, respectively. An activity monitor worn for seven days was used to generate performance metrics of mean daily steps and weekly moderate intensity walking minutes. Univariate linear regression analyses were used to examine associations between each capacity and performance measure in the full sample and less and more active subgroups.Walking capacity significantly contributed to daily steps in the full sample (endurance: RWalking capacity contributed to, but explained a relatively small portion of the variance in, real-world walking performance. The contribution was somewhat greater in less active individuals. The study adds support to the idea that clinically measured walking capacity may have limited benefit for understanding real-world walking performance in PD. Factors beyond walking capacity may better account for actual walking behavior.
- Published
- 2022